CRDL

0.86262.28%
TL

Teri Loxam

Independent Director

Ms. Teri Loxam, M.B.A. has been the Chief Financial Officer at COMPASS Pathways plc since March 01, 2024. Ms. Loxam served as Chief Operating Officer & Chief Financial Officer at Kira Pharmaceuticals. She served as Chief Financial Officer at Gameto Inc. since April 2023 until 2023. She was Chief Financial Officer at SQZ Biotechnologies Company since September 2019 until November 11, 2021. She serves as Independent Director at Cardiol Therapeutics Inc. since May 19, 2022. Ms. Loxam joined SQZ with deep experience in investor relations, strategy, corporate communications and finance. At SQZ, Ms. Loxam was responsible for leading the financial and investor activities. She serves as an Independent Director at Vaxcyte, inc. since September 2021. Ms. Loxam has experience in the pharmaceutical industry and joined the SQZ team from Merck & Co. From August 2015 to August 2019, Ms. Loxam was at Merck & Co. Inc. a global healthcare company, where she served as Senior Vice President of Investor Relations and Global Communications. Ms. Loxam served as Vice President Investor Relations at IMAX Corporation since July 2012 until August 2015. She served as Executive Director of Investor Relations at Bristol-Myers Squibb from September 2009 to July 2012. She served as Director of Treasury Planning & Analysis Bristol-Myers Squibb from July 2008 to September 2009 and served as its Director of Strategic Planning & Portfolio Mgmt from June 2003 to July 2008. Ms. Loxam also spent eleven years at Bristol-Myers Squibb, where she held positions of increasing responsibility across strategic planning and portfolio management, treasury and investor relations. Ms. Loxam received an MBA from University of California, Irvine - The Paul Merage School of Business in 2001 and B.Sc in Biology from University of Victoria in 1994.

Positions